About: Serum dextromethorphan/dextrorphan metabolic ratio for CYP2D6 phenotyping in clinical practice

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Serum dextromethorphan/dextrorphan metabolic ratio for CYP2D6 phenotyping in clinical practice Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	skos:Concept http://linked.opendata.cz/ontology/domain/vavai/Vysledek
rdfs:seeAlso	http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2710.2012.01333.x/abstract
Description	What is known and Objective: Accurate prediction of actual CYP2D6 metabolic activity may prevent some adverse drug reactions and improve therapeutic response in patients receiving CYP2D6 substrates. Dextromethorphan-to-dextrorphan metabolic ratio (MRDEM/DOR) is well established as a marker of CYP2D6 metabolizer status. The relationship between urine and plasma or serum MRDEM/DOR is not well established nor is there evidence of antimode for separation of intermediate and especially poor metabolizers (PM) from extensive metabolizers (EM). This study addressed whether CYP2D6 phenotyping using molar metabolic ratio of dextromethorphan to dextrorphan (MRDEM/DOR) in serum is usable and reliable in clinical practice as urinary MRDEM/DOR. Methods: We measured MRDEM/DOR in serum and CYP2D6 genotype in 51 drug-naive patients and 30 volunteers. Receiver-operator characteristic (ROC) analysis was used for the evaluation of optimum cut-off value for discriminating between extensive, intermediate and PM. What is known and Objective: Accurate prediction of actual CYP2D6 metabolic activity may prevent some adverse drug reactions and improve therapeutic response in patients receiving CYP2D6 substrates. Dextromethorphan-to-dextrorphan metabolic ratio (MRDEM/DOR) is well established as a marker of CYP2D6 metabolizer status. The relationship between urine and plasma or serum MRDEM/DOR is not well established nor is there evidence of antimode for separation of intermediate and especially poor metabolizers (PM) from extensive metabolizers (EM). This study addressed whether CYP2D6 phenotyping using molar metabolic ratio of dextromethorphan to dextrorphan (MRDEM/DOR) in serum is usable and reliable in clinical practice as urinary MRDEM/DOR. Methods: We measured MRDEM/DOR in serum and CYP2D6 genotype in 51 drug-naive patients and 30 volunteers. Receiver-operator characteristic (ROC) analysis was used for the evaluation of optimum cut-off value for discriminating between extensive, intermediate and PM. (en)
Title	Serum dextromethorphan/dextrorphan metabolic ratio for CYP2D6 phenotyping in clinical practice Serum dextromethorphan/dextrorphan metabolic ratio for CYP2D6 phenotyping in clinical practice (en)
skos:prefLabel	Serum dextromethorphan/dextrorphan metabolic ratio for CYP2D6 phenotyping in clinical practice Serum dextromethorphan/dextrorphan metabolic ratio for CYP2D6 phenotyping in clinical practice (en)
skos:notation	RIV/00216224:14740/12:00060574!RIV13-MZ0-14740___
http://linked.open...avai/riv/aktivita	P
http://linked.open...avai/riv/aktivity	P(ED1.1.00/02.0068), P(NS9676)
http://linked.open...iv/cisloPeriodika	4
http://linked.open...vai/riv/dodaniDat	2013
http://linked.open...aciTvurceVysledku	Juřica, Jan Šulcová, Alexandra Žourková, Alexandra Barteček, Richard Zendulka, Ondřej Pindurová, Eva Kašpárek, Tomáš
http://linked.open.../riv/druhVysledku	J - Článek v odborném periodiku
http://linked.open...iv/duvernostUdaju	S - Úplné a pravdivé údaje nepodléhající ochraně podle zvláštních právních předpisů
http://linked.open...titaPredkladatele	Masarykova univerzita / Středoevropský technologický institut
http://linked.open...dnocenehoVysledku	167557
http://linked.open...ai/riv/idVysledku	RIV/00216224:14740/12:00060574
http://linked.open...riv/jazykVysledku	eng - angličtina
http://linked.open.../riv/klicovaSlova	CYP2D6; dextromethorphan; genotype; metabolic ratio; phenotype; serum (en)
http://linked.open.../riv/klicoveSlovo	genotype phenotype dextromethorphan metabolic ratio CYP2D6 serum
http://linked.open...odStatuVydavatele	US - Spojené státy americké
http://linked.open...ontrolniKodProRIV	[E25E4A36EEAE]
http://linked.open...i/riv/nazevZdroje	JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
http://linked.open...in/vavai/riv/obor	FR
http://linked.open...ichTvurcuVysledku	7 (xsd:int)
http://linked.open...cetTvurcuVysledku	7 (xsd:int)
http://linked.open...vavai/riv/projekt	Central european institute of technology The influence of pharmacogenetic and pharmacokinetic factors on the efficacy and safety of the first schizophrenia episodes therapy
http://linked.open...UplatneniVysledku	2012
http://linked.open...v/svazekPeriodika	37
http://linked.open...iv/tvurceVysledku	Barteček, Richard Juřica, Jan Kašpárek, Tomáš Pindurová, Eva Šulcová, Alexandra Žourková, Alexandra Zendulka, Ondřej
http://linked.open...ain/vavai/riv/wos	000305894800020
issn	0269-4727
number of pages	5 (xsd:int)
http://bibframe.org/vocab/doi	10.1111/j.1365-2710.2012.01333.x
http://localhost/t...ganizacniJednotka	14740

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 48 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software